Clinical Trial Update: Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing ruxolitinib to allogeneic stem cell transplantation for myelofibrosis, with enrollment guided by donor availability; currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Universitätsklinikum Hamburg-Eppendorf | Conditions: Bone Marrow Fibrosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING